TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Enlivex ( (ENLV) ).
Enlivex Therapeutics Ltd. announced positive six-month topline data from the Phase IIa stage of its Allocetra™ trial for moderate to severe knee osteoarthritis, reaffirming previous three-month results. The study demonstrated significant pain reduction and improved function in patients aged 60 and above, with sustained efficacy and a favorable safety profile, supporting further development and commercial potential.
The most recent analyst rating on (ENLV) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.
Spark’s Take on ENLV Stock
According to Spark, TipRanks’ AI Analyst, ENLV is a Underperform.
Enlivex’s financial challenges, characterized by no revenue and ongoing cash burn, significantly impact its stock score. Technical indicators show neutral momentum, but the negative valuation metrics reflect ongoing financial difficulties. The absence of positive corporate events or earnings call data limits the potential for a higher score.
To see Spark’s full report on ENLV stock, click here.
More about Enlivex
Enlivex Therapeutics Ltd. is a clinical-stage company specializing in macrophage reprogramming immunotherapy. The company is developing Allocetra™, a universal, off-the-shelf cell therapy aimed at reprogramming macrophages into their homeostatic state to address life-threatening and debilitating conditions.
Average Trading Volume: 181,178
Technical Sentiment Signal: Sell
Current Market Cap: $21.4M
Learn more about ENLV stock on TipRanks’ Stock Analysis page.